{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:26Z","timestamp":1761901826547,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.msard.2021.103148","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:43:46Z","timestamp":1626180226000},"page":"103148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting"],"prefix":"10.1016","volume":"54","author":[{"given":"Geraldine G.","family":"Luetic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Laura","family":"Menichini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2021.103148_bib0001","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","article-title":"Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose","volume":"56","author":"Alam","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9056","key":"10.1016\/j.msard.2021.103148_bib0002","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2021.103148_bib0003","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1177\/1352458518793527","article-title":"Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis","volume":"25","author":"Bove","year":"2019","journal-title":"Mult. Scler"},{"issue":"22","key":"10.1016\/j.msard.2021.103148_bib0004","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"year":"2012","series-title":"Oral Versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis","author":"Burton","key":"10.1016\/j.msard.2021.103148_bib0005"},{"issue":"2","key":"10.1016\/j.msard.2021.103148_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4321\/S1699-695X2015000200005","article-title":"Que inyectables pueden ser administrados por v\u00eda oral o enteral?","volume":"8","author":"Candel","year":"2015","journal-title":"Art. Esp. Rev. Cl\u00edn. Med. Fam."},{"issue":"2","key":"10.1016\/j.msard.2021.103148_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/S0317167100053804","article-title":"Treatment optimization in multiple sclerosis","volume":"31","author":"Freedman","year":"2004","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2021.103148_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Canadian Multiple Sclerosis Working Group. Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2021.103148_bib0009","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nurt.2007.07.008","article-title":"Corticosteroids for multiple sclerosis: i. application for treating exacerbations","volume":"4","author":"Frohmann","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2021.103148_bib0010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103148_bib0011","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00415-017-8505-0","article-title":"Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis","volume":"264","author":"Lattanzi","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103148_bib0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2021.103148_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188644","article-title":"Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2021.103148_bib0014","article-title":"Administraci\u00f3n oral de preparado parenteral de vitamina K en anticoagulaci\u00f3n excesiva por warfarina [Oral administration of intravenous preparation of Vitamin K for excessive anticoagulation due to warfarin","volume":"72","author":"Lozada","year":"2012","journal-title":"Medicina (B Aires"},{"key":"10.1016\/j.msard.2021.103148_bib0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the Clinical Course of Multiple Sclerosis: the 2013 revisions.","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2021.103148_bib0016","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","article-title":"A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS","volume":"73","author":"Martinelli","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2021.103148_bib0017","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.103148_bib0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1191\/1352458504ms1068oa","article-title":"Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis","volume":"10","author":"Nos","year":"2004","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.103148_bib0019","first-page":"73","article-title":"Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data","volume":"23","author":"Pascual","year":"2008","journal-title":"Neurologia"},{"issue":"6","key":"10.1016\/j.msard.2021.103148_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103148_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","author":"Salter","year":"2021","journal-title":"JAMA Neurol. [Internet]"},{"issue":"102449","key":"10.1016\/j.msard.2021.103148_bib0022","article-title":"Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes","volume":"46","author":"Segamarchi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103148_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.msard.2018.11.018","article-title":"Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis","volume":"27","author":"Sol\u00e0-Valls","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.103148_bib0024","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and Coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103148_bib0025","first-page":"105","article-title":"Injectable dexamethasone sodium phosphate administered orally? A pharmacokinetic analysis of a common emergency department practice","volume":"20","author":"Toledo","year":"2015","journal-title":"J. Pediatr. Pharmacol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:59:01Z","timestamp":1761901141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":25,"alternative-id":["S2211034821004156"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103148","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103148"}}